Please login to the form below

Glybera

This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.

Bluebird puts €1.57m price on gene therapy Zynteglo

Zynteglo won't be the first ever 1m plus gene therapy launched in Europe - that distinction went to UniQure's rare disease treatment Glybera, which was launched in 2012.

Latest news

UniQure gets speedy US review for Huntington’s gene therapy

a-year Glybera back in 2012.
J&J bolsters gene therapy unit with $100m MeiraGTx deal

In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in 2012 but was withdrawn five years later for commercial reasons.
AZ makes gene therapy move with 4DMT alliance

While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut
UniQure’s starts pivotal haemophilia B gene therapy trial

UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Assessing the risks in annuity pricing models

Three others (ChondroCelect, PROVENGE and Glybera) were withdrawn, partly due to challenges associated with reimbursement.
Bluebird: on a mission to ‘recode’ the DNA of healthcare

Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera.
Bluebird Bio: on the cusp of a gene therapy revolution

success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera
Health on instalment

Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
Rare diseases: meeting the challenge

Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

Basilea's Hans Christian Rohde takes up commercial role at uniQure

In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Solaris Health looks at the gene therapy revolution

There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Principal Medical Writer: Varies on experience

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

PMHub

Add my company

Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....